Australia markets open in 5 hours 53 minutes

Isracann Biosciences Inc. (IPOT.CN)

Canadian Sec - Canadian Sec Real-time price. Currency in CAD
Add to watchlist
0.01500.0000 (0.00%)
At close: 10:41AM EDT
Currency in CAD

Valuation measures4

Market cap (intra-day) 2.64M
Enterprise value 2.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.54
Price/book (mrq)20.60
Enterprise value/revenue 72.32
Enterprise value/EBITDA -0.35

Trading information

Stock price history

Beta (5Y monthly) 0.03
52-week change 30.00%
S&P500 52-week change 326.27%
52-week high 30.0150
52-week low 30.0150
50-day moving average 30.0150
200-day moving average 30.0150

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5175.99M
Implied shares outstanding 6175.99M
Float 8175.79M
% held by insiders 10.17%
% held by institutions 10.00%
Shares short (15 Apr 2024) 4240
Short ratio (15 Apr 2024) 4N/A
Short % of float (15 Apr 2024) 4N/A
Short % of shares outstanding (15 Apr 2024) 4N/A
Shares short (prior month 15 Mar 2024) 4240

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:3
Last split date 317 Oct 2019

Financial highlights

Fiscal year

Fiscal year ends N/A
Most-recent quarter (mrq)N/A

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-34.99%
Return on equity (ttm)-252.75%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -2.19M
Net income avi to common (ttm)-4.54M
Diluted EPS (ttm)-0.0300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)198.05k
Total cash per share (mrq)0
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.29
Book value per share (mrq)0.00

Cash flow statement

Operating cash flow (ttm)-1.48M
Levered free cash flow (ttm)-567.05k